Compare ARK Genomic Revolution ETF (ARKG) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Tripadvisor Inc Common Stock — how do they compare? ARK Genomic Revolution ETF trades at $44.31, while Tripadvisor Inc Common Stock trades at $11.04 (market cap $1.26B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| ARKG | TRIP | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $19.14 |
52-Week Low | $24.02 | $9.24 |
Market Cap | — | $1.26B |
Enterprise Value | — | $1.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Tripadvisor (TRIP) trades at $10.78, up 3.45% today, but faces bearish technical signals with recent earnings misses. The company maintains strong gross margins at 92.11% but struggles with thin net income margins of 0.27%. Recent Q2 2026 results missed expectations, though the $700M sale of TheFork to American Express provides strategic focus and cash infusion. Analyst consensus is mixed with 62.5% hold ratings and a $13.71 price target suggesting 27% upside potential from current levels.
TRIP presents a turnaround opportunity with simplified operations post-TheFork sale and Viator's growth potential, but faces persistent search-related pressures and uneven travel demand. The stock trades at reasonable valuations (P/S 0.7x) but carries execution risks amid competitive threats. Cash flow trends show volatility, with negative net cash flow projected for 2026, requiring careful monitoring of the company's strategic execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
